Citius Oncology Inc. (CTOR)
NASDAQ: CTOR
· Real-Time Price · USD
1.91
0.02 (1.06%)
At close: Oct 03, 2025, 3:59 PM
Citius Oncology Income Statement
Financials in USD. Fiscal
year is
October - September.
| Fiscal Year | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Apr 30, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -25.48M | -20.92M | -13.72M | -11.9M | -5.66M | -5.47M | -5.35M | -907.05K | -7.9M | -10M | -9.85M | -9.71M | -2.3M | n/a |
Interest Income | n/a | 636.42K | 1.39M | 2.67M | 3.25M | 3.43M | 3.43M | 2.65M | 2.07M | 1.25M | 493.02K | n/a | n/a | n/a |
Pretax Income | -25.64M | -20.28M | -12.32M | -10.51M | -8.88M | -8.52M | -8.4M | -3.43M | -5.81M | -8.72M | -9.33M | -9.71M | -2.31M | -9.39K |
Net Income | -26.58M | -25.98M | -23.08M | -21.15M | -14.34M | -8.95M | -3.5M | 1.6M | 1.6M | -1.31M | -1.93M | -2.31M | -2.31M | -9.39K |
Selling & General & Admin | 18.84M | 18.33M | 17.34M | 15.65M | 14.17M | 12.02M | 10.54M | 7.88M | 6.16M | 5.5M | 3.63M | 2.86M | 685.5K | n/a |
Research & Development | 6.64M | 6.83M | 5.04M | 4.93M | 4.78M | 4.88M | 4.45M | 4.24M | 8.33M | 8.71M | 7.79M | 6.86M | 1.61M | n/a |
Other Expenses | n/a | n/a | n/a | n/a | -4.62M | -7.01M | -9.64M | -11.21M | -6.59M | -4.21M | -1.57M | n/a | n/a | n/a |
Operating Expenses | 25.48M | 25.16M | 22.38M | 20.57M | 14.33M | 9.9M | 5.35M | 907.05K | 7.9M | 10M | 9.85M | 9.71M | 2.3M | n/a |
Interest Expense | 160.75K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 25.48M | 25.16M | 22.38M | 20.57M | 14.33M | 9.9M | 5.35M | 907.05K | 7.9M | 10M | 9.85M | 9.71M | 2.3M | n/a |
Income Tax Expense | 936.72K | 816.48K | 696.24K | 576K | 576K | 434.73K | 293.66K | 151.51K | 16.07K | 15.65K | 12.72K | 10.87K | 2.3K | n/a |
Shares Outstanding (Basic) | 71.55M | 71.55M | 71.55M | 71.55M | 66.53M | 66.53M | 89.41M | 89.42M | 90.16M | 90.16M | 90.16M | 90.16M | 81.4M | 66.42M |
Shares Outstanding (Diluted) | 71.55M | 71.55M | 71.55M | 71.55M | 66.53M | 66.53M | 89.41M | 89.42M | 90.16M | 90.16M | 90.16M | 90.16M | 81.4M | 66.42M |
EPS (Basic) | -0.38 | -0.37 | -0.33 | -0.3 | -0.18 | -0.05 | 0.09 | 0.20 | 0.18 | 0.08 | 0.01 | -0.03 | -0.04 | -0.00 |
EPS (Diluted) | -0.38 | -0.37 | -0.33 | -0.3 | -0.18 | -0.05 | 0.09 | 0.20 | 0.18 | 0.08 | 0.01 | -0.03 | -0.04 | -0.00 |
EBITDA | -25.48M | -20.28M | -12.32M | -4.89M | 1.93M | 2.3M | 2.42M | 1.77M | 1.61M | 992.54K | 380.81K | n/a | -9.39K | -9.39K |
EBIT | -25.48M | -20.28M | -12.32M | -4.89M | 1.93M | 2.3M | 2.42M | 1.77M | -5.81M | -8.72M | -9.33M | -9.71M | -2.31M | -9.39K |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |